See also this year's filing and all EDGAR filings for this company.
PDF Report 0001693011_2023_Inozyme_Pharma_Inc.pdf
Logs
warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001693011, Inozyme Pharma Inc.
xvar | xval | |
---|---|---|
0 | AssetsCurrent | 131,393,000 |
1 | IntangibleAssetsNetIncludingGoodwill | 0 |
2 | PropertyPlantAndEquipmentNet | 2,018,000 |
3 | remainder_Assets | 5,784,000 |
4 | LiabilitiesCurrent | 14,715,000 |
5 | LiabilitiesNoncurrent | 1,947,000 |
6 | remainder_Liabilities | 4,139,000 |
7 | CostOfGoodsAndServicesSold | 0 |
8 | SellingGeneralAndAdministrativeExpense | 20,826,000 |
9 | ResearchAndDevelopmentExpense | 47,849,000 |
10 | remainder_Expenses | 0 |
11 | remainder_Revenues | 0 |
12 | remainder_NetIncome | 1,614,000 |
13 | remainder_ComprehensiveNetIncome | -223,000 |
yvar | yval | |
---|---|---|
0 | Assets | 139,195,000 |
1 | Liabilities | 20,801,000 |
2 | Expenses | 68,675,000 |
3 | Revenues | 0 |
4 | StockholdersEquity | 118,394,000 |
5 | NetIncome | -67,061,000 |
6 | ComprehensiveNetIncome | -67,172,500 |
7 | BaseVar | 115,254,000 |
8 | EconomicCapitalRatio | 1.71 |